Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
A61K-039/07
C12N-007/00
출원번호
US-0870570
(2015-09-30)
공개번호
US-0114020
(2016-04-28)
발명자
/ 주소
Huang, Chun-Ming
Zhang, JianFeng
Tang, De-Chu
출원인 / 주소
Huang, Chun-Ming
인용정보
피인용 횟수 :
0인용 특허 :
0
초록▼
The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and the
The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.
대표청구항▼
1-57. (canceled) 58. A non-invasive method of inducing a protective immune response against inhalation anthrax in a mammal, comprising: administering intranasally to the mammal at least 107 pfu of a non-replicating adenovirus vector that contains and expresses a nucleic acid encoding B. anthracis pr
1-57. (canceled) 58. A non-invasive method of inducing a protective immune response against inhalation anthrax in a mammal, comprising: administering intranasally to the mammal at least 107 pfu of a non-replicating adenovirus vector that contains and expresses a nucleic acid encoding B. anthracis protective antigen, B. anthracis lethal factor or fragment thereof,wherein induction of the protective immune response provides protection against challenge with intranasal inhalation of B. anthracis spores, and thereby non-invasively inducing a protective immune response against inhalation anthrax in the mammal. 59. The method of claim 58, wherein the mammal is a companion animal, a domesticated animal, a food- or feed-producing animal, a livestock animal, a game animal, a racing animal, or a sport animal. 60. The method of claim 58, wherein the mammal is a cow, a horse, a dog, a cat, a goat, a sheep, or a pig. 61. The method of claim 58, wherein the mammal is a human. 62. The method of claim 58, wherein the vector is E1 and/or E3 defective adenovirus serotype 5 (Ad5). 63. The method of claim 58, wherein the B. anthracis lethal factor is fragment LF7. 64. The method of claim 58, wherein the B. anthracis protective antigen is PA83. 65. A non-invasive method of inducing a systemic immune response against B. anthracis in a mammal, comprising: administering intranasally to the mammal at least 107 pfu of a non-replicating adenovirus vector that contains and expresses a nucleic acid encoding B. anthracis protective antigen, B. anthracis lethal factor or fragment thereof,wherein the mammal produces toxin-neutralizing antibodies in response to the intranasal administration of the adenovirus vector encoding B. anthracis protective antigen, B. anthracis lethal factor or fragment thereof,wherein the toxin-neutralizing antibodies provide a protective immune response against challenge with intranasal inhalation of B. anthracis spores, and thereby non-invasively inducing a systemic protective immune response against B. anthracis in the mammal. 66. The method of claim 65, wherein the vector is E1 and/or E3 defective adenovirus serotype 5 (Ad5). 67. The method of claim 65, wherein the mammal is a companion animal, a domesticated animal, a food- or feed-producing animal, a livestock animal, a game animal, a racing animal, or a sport animal. 68. The method of claim 65, wherein the mammal is a cow, a horse, a dog, a cat, a goat, a sheep, or a pig. 69. The method of claim 65, wherein the mammal is a human. 70. The method of claim 65, wherein the B. anthracis lethal factor is fragment LF7. 71. The method of claim 65, wherein the B. anthracis protective antigen is PA83.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.